Cargando…
Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achie...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467753/ https://www.ncbi.nlm.nih.gov/pubmed/26089694 http://dx.doi.org/10.2147/DMSO.S50659 |
_version_ | 1782376408255823872 |
---|---|
author | Raffaelli, Marco Sessa, Luca Mingrone, Geltrude Bellantone, Rocco |
author_facet | Raffaelli, Marco Sessa, Luca Mingrone, Geltrude Bellantone, Rocco |
author_sort | Raffaelli, Marco |
collection | PubMed |
description | The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achieve the improvements in diabetic remission observed after bariatric-metabolic surgery. Several studies have demonstrated that bariatric-metabolic surgery is an effective treatment for type 2 diabetes when compared with conventional nonsurgical medical treatment. Because the best results are achievable in patients with a relatively short history of diabetes and less advanced controlled disease, the surgical option could be considered early, especially in morbid obese subjects (BMI ≥35 kg/m(2)) after failure of medical treatment. Patients with extensive weight loss are more likely to achieve type 2 diabetes remission after bariatric surgery. At present, Roux-en-Y gastric bypass seems the surgical procedure of choice because it has fewer risks than biliopancreatic diversion, and it is associated with higher weight loss and metabolic improvements compared with adjustable gastric banding. Recent evidences regarding the effectiveness of sleeve gastrectomy in diabetes remission have to be confirmed by controlled trials with longer follow-up. |
format | Online Article Text |
id | pubmed-4467753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44677532015-06-18 Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? Raffaelli, Marco Sessa, Luca Mingrone, Geltrude Bellantone, Rocco Diabetes Metab Syndr Obes Review The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achieve the improvements in diabetic remission observed after bariatric-metabolic surgery. Several studies have demonstrated that bariatric-metabolic surgery is an effective treatment for type 2 diabetes when compared with conventional nonsurgical medical treatment. Because the best results are achievable in patients with a relatively short history of diabetes and less advanced controlled disease, the surgical option could be considered early, especially in morbid obese subjects (BMI ≥35 kg/m(2)) after failure of medical treatment. Patients with extensive weight loss are more likely to achieve type 2 diabetes remission after bariatric surgery. At present, Roux-en-Y gastric bypass seems the surgical procedure of choice because it has fewer risks than biliopancreatic diversion, and it is associated with higher weight loss and metabolic improvements compared with adjustable gastric banding. Recent evidences regarding the effectiveness of sleeve gastrectomy in diabetes remission have to be confirmed by controlled trials with longer follow-up. Dove Medical Press 2015-06-08 /pmc/articles/PMC4467753/ /pubmed/26089694 http://dx.doi.org/10.2147/DMSO.S50659 Text en © 2015 Raffaelli et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Raffaelli, Marco Sessa, Luca Mingrone, Geltrude Bellantone, Rocco Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? |
title | Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? |
title_full | Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? |
title_fullStr | Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? |
title_full_unstemmed | Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? |
title_short | Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? |
title_sort | assessing the obese diabetic patient for bariatric surgery: which candidate do i choose? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467753/ https://www.ncbi.nlm.nih.gov/pubmed/26089694 http://dx.doi.org/10.2147/DMSO.S50659 |
work_keys_str_mv | AT raffaellimarco assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose AT sessaluca assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose AT mingronegeltrude assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose AT bellantonerocco assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose |